Statistical scrutiny soft- ware originpro 8 sr0 v8 buy xeloda mastercard cancer-fighting foods by health research.
\n<\/p>\n
Table 6 shows the adverse reactions occurring in5of patients from pooling the two phase 3 trials in first line metastatic colorectal cancerA total of 596 patients with metastatic colorectal cancer were treated with 1250 mg\/m 2 twice a day of XELODA administered for 2 weeks followed by a 1-week rest periodand 593 patients were administered 5-FU and leucovorin in the Mayo regimen20 mg\/m 2 leucovorin IV followed by 425 mg\/m 2 IV bolus 5-FUon days 1-5every 28 daysIn the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU\/LV-treated patientsA total of 7813and 6311capecitabine and 5-FU\/LVtreated patientsrespectivelydiscontinued treatment because of adverse reactions\/intercurrent illnessA total of 82 deaths due to all causes occurred either on study or within 28 days of receiving study drug508.4patients randomized to XELODA and 325.4randomized to 5-FU\/LV.<\/p>\n
The dose reduction schedule for docetaxel when used in combination with XELODA for the treatment of metastatic breast cancer is shown in Table 3.<\/p>\n
In both trialsoverall survivaltime to progression and response ratecomplete plus partial responseswere assessedResponses were defined by the World Health Organization criteria and submitted to a blinded independent review committeeIRCDifferences in assessments between the investigator and IRC were reconciled by the sponsorblinded to treatment armaccording to a specified algorithmSurvival was assessed based on a non-inferiority analysis.<\/p>\n